Table 4 |
||||||||
|
Manifestations of definite SSc at routine examinations in early SSc and UCTD patients at follow-up |
||||||||
|
Early SSc (n = 39) |
UCTD (n = 37) |
P† |
||||||
|
|
||||||||
|
1° y |
2° y |
3° y |
4° y |
5° y |
1° y |
2° y* |
||
|
Digital ulcers/scars |
4 |
5 |
5 |
5 |
5 (12.8) |
0 |
1 (2.7) |
|
|
Teleangeactasias (≥2) |
7 |
9 |
10 |
10 |
14 (35.9) |
0 |
0 |
|
|
Skin sclerosis |
0 |
3 |
4 |
4 |
4 (10.2) |
0 |
0 |
|
|
mRSS (median, range) |
- |
2 |
3.5 (2 to 8) |
3.5 (2 to 8) |
||||
|
Chest X-ray bibasilar lung fibrosis |
2 |
2 |
2 |
2 |
2 (5.1) |
0 |
1 (2.7) |
|
|
Esophageal dysmotility at barium X-ray |
2 |
2 |
2 |
2 |
3 (7.7) |
3 (8.1) |
||
|
Cardiac blocks and/or Q waves |
0 |
0 |
1 |
2 |
2 (5.1) |
0 |
0 |
|
|
TOTAL |
30 (76.9) |
5 (13.5) |
< 0.0001 |
|||||
|
|
||||||||
|
All data are expressed as numbers and percentages (in brackets). mRSS, modified Rodnan Skin Score; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease; y, year. † statistical difference at the end of the follow-up period; *none of the UCTD patients developed further manifestations of definite SSc after the second year of follow-up. |
||||||||
|
Valentini et al. Arthritis Research & Therapy 2012 14:R188 doi:10.1186/ar4019 |
||||||||